(Bloomberg) — The Covid-19 vaccine booster shot proposed by Pfizer Inc. and BioNTech SE should be given to a smaller group of people who are the most vulnerable to serious disease, a panel of expert advisers to the U.S. Food and Drug Administration said.
The FDA and Pfizer had originally proposed approving a booster shot for everyone 16 and older. But the advisers rejected that idea out of concern that the data to support such a broad application was thin and there could be risks, especially for younger people.
Instead, the panel voted 18-0 in favor of an emergency-use authorization — a more limited clearance than a full approval — for people 65 and older or individuals at high risk of severe Covid-19.
The move is a setback to a sweeping plan from the Biden administration to roll out booster shots to a broad population next week. But it will still allow U.S. health officials to target third doses at people at highest risk of getting seriously ill or dying from Covid-19.
Video: Will FDA approval for Pfizer vaccine boost shots in arms? (CNBC)
The FDA will still need to grant a final clearance. And an outside advisory panel to the Centers for Disease Control and Prevention will also make detailed recommendations for the use of the booster shot at a meeting next week.
(Updates with more detail on voting plans throughout)
More stories like this are available on bloomberg.com
©2021 Bloomberg L.P.Internet Explorer Channel Network